HR 4244 116th Congress House

MAGIC Act

Official title: To provide for a pathway for chemically synthesized insulin to be approved under an abbreviated new drug application submitted under the Federal Food, Drug, and Cosmetic Act, and for other purposes.

Introduced: December 23, 2019 Introduced by: Kelly, Mike Republican · Pennsylvania See on congress.gov

Health Competition and antitrustDigestive and metabolic diseasesDrug safety, medical device, and laboratory regulationLicensing and registrations

More subjectsShow fewer subjects

ManufacturingPrescription drugs

Everywhere this bill has been 3 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Sep 10, 2019

Referred to the Subcommittee on Health.

Sep 9, 2019

Referred to the House Committee on Energy and Commerce.

Sep 9, 2019

Introduced in House

Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

Latest action September 10, 2019

Referred to the Subcommittee on Health.

Plain-English summary Congressional Research Service

Market Access for Generic Insulin Competition or the MAGIC Act

This bill provides a pathway for the Food and Drug Administration to approve chemically synthesized insulin or an analogue of chemically synthesized insulin as a generic drug under the abbreviated new drug application process.

Bill text 1 version